Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 793504, 6 pages
http://dx.doi.org/10.1155/2014/793504
Research Article

In Search of the Active Metabolites of an Anticancer Piperazinedione, TW01003, in Rats

1School of Pharmacy, College of Pharmacy, Taipei Medical University, No. 250, Wu-Hsing Street, Taipei 110, Taiwan
2Research and Development Center, United Biomedical, Inc., Asia, No. 45, Guangfu N. Road, Hukou, Hsinchu 303, Taiwan
3Department of Nursing, Yuanpei University, No. 306, Yuanpei Street, Xiangshan District, Hsinchu 300, Taiwan

Received 30 December 2013; Accepted 2 March 2014; Published 17 April 2014

Academic Editor: Dongquan Shi

Copyright © 2014 Chun-Li Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Dumontet and M. A. Jordan, “Microtubule-binding agents: a dynamic field of cancer therapeutics,” Nature Reviews Drug Discovery, vol. 9, no. 10, pp. 790–803, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Pellegrini and D. R. Budman, “Review: tubulin function, action of antitubulin drugs, and new drug development,” Cancer Investigation, vol. 23, no. 3, pp. 264–273, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. R. O. Carlson, “New tubulin targeting agents currently in clinical development,” Expert Opinion on Investigational Drugs, vol. 17, no. 5, pp. 707–722, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. R. A. Stanton, K. M. Gernert, J. H. Nettles, and R. Aneja, “Drugs that target dynamic microtubules: a new molecular perspective,” Medicinal Research Reviews, vol. 31, no. 3, pp. 443–481, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. C. M. Teng, H. P. Wang, E. I. C. Li et al., “Piperazinedione compounds,” US Patent no. 6,635,649 B2, October 2003.
  6. M. C. Chen, C. H. Chen, Y. N. Liu et al., “TW01001, a novel piperazinedione, induces mitotic arrest and autophagy in non-small cell lung cancer A549 cells,” Cancer Letter, vol. 336, no. 2, pp. 370–378, 2013. View at Google Scholar
  7. C. M. Teng, H. P. Wang, E. I. C. Li et al., “Piperazinedione compounds,” US Patent No. 7,288,545 B2, October 2007.
  8. Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Guide for the Care and Use of Laboratory Animals, The National Academies Press, Washington, DC, USA, 8th edition, 2011.
  9. C.-L. Wang, P.-R. Hsueh, M.-J. Sun et al., “PBA-ω-Lys as sustained phenylbutyrate-releasing prodrug,” Journal of Food and Drug Analysis, vol. 18, no. 6, pp. 371–379, 2010. View at Google Scholar · View at Scopus
  10. S. Riegelmen and P. Collier, “The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time,” Journal of Pharmacokinetics and Biopharmaceutics, vol. 8, no. 5, pp. 509–534, 1980. View at Google Scholar · View at Scopus
  11. S. A. Kaplan, M. L. Jack, S. Cotler, and K. Alexander, “Utilization of area under the curve to elucidate the disposition of an extensively biotransformed drug,” Journal of Pharmacokinetics and Biopharmaceutics, vol. 1, no. 3, pp. 201–216, 1973. View at Google Scholar · View at Scopus
  12. C.-S. Shia, S.-Y. Tsai, S.-C. Kuo, Y.-C. Hou, and P.-D. L. Chao, “Metabolism and pharmacokinetics of 3,3′,4′,7- tetrahydroxyflavone (fisetin), 5-hydroxyflavone, and 7-hydroxyflavone and antihemolysis effects of fisetin and its serum metabolites,” Journal of Agricultural and Food Chemistry, vol. 57, no. 1, pp. 83–89, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. C. A. Strott, “Sulfonation and molecular action,” Endocrine Reviews, vol. 23, no. 5, pp. 703–732, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. F. C. Kauffman, “Sulfonation in pharmacology and toxicology,” Drug Metabolism Reviews, vol. 36, no. 3-4, pp. 823–843, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Glatt, H. Boeing, C. E. H. Engelke et al., “Human cytosolic sulphotransferases: genetics, characteristics, toxicological aspects,” Mutation Research: Fundamental and Molecular Mechanisms of Mutagenesis, vol. 482, no. 1-2, pp. 27–40, 2001. View at Google Scholar · View at Scopus
  16. M. Negishi, L. G. Pedersen, E. Petrotchenko et al., “Structure and function of sulfotransferases,” Archives of Biochemistry and Biophysics, vol. 390, no. 2, pp. 149–157, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Trottier, P. Milkiewicz, J. Kaeding, M. Verreault, and O. Barbier, “Coordinate regulation of hepatic bile acid oxidation and conjugation by nuclear receptors,” Molecular Pharmaceutics, vol. 3, no. 3, pp. 212–222, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Glatt, “Sulfotransferases in the bioactivation of xenobiotics,” Chemico-Biological Interactions, vol. 129, no. 1-2, pp. 141–170, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. Y.-J. Surh, “Bioactivation of benzylic and allylic alcohols via sulfo-conjugation,” Chemico-Biological Interactions, vol. 109, no. 1–3, pp. 221–235, 1998. View at Publisher · View at Google Scholar · View at Scopus